Preconditioning in experimental studies
=======================================

In 1986, a group of investigators studying the intracellular changes of glycolytic products at different time points of myocardial ischemia in a canine model, observed that four cycles of 5 minutes ischemia and reperfusion prior to a more sustained episode of 40 min ischemia reduced considerably myocardial infarction compared with the control ([@b63]). This was the first description of an endogenous protective phenomenon called ischemic preconditioning. The same beneficial effect was since then confirmed in every species that was studied, independently of the presence of collaterals in the coronary circulation and independently of the size of the animal model ([@b78]; [@b53]; [@b56]). Early studies mostly focused on the investigation of the natural history of preconditioning in terms of the number of brief ischemic episodes, the duration of each ischemic insult, the duration of the reperfusion interval that would separate the last cycle of preconditioning from the following sustained episode of ischemia and finally the duration of the prolonged ischemia in order the preconditioning to be effective ([@b53]; [@b34]). Species differences were observed regarding the number of brief episodes of ischemia: increased number of ischemic bursts was effective in protecting the dog heart ([@b53]) whereas protection was lost after a certain number of ischemic-reperfusion stimuli in the rabbit heart ([@b53]; [@b35]).

The preconditioned state is very transient following a preconditioning protocol and lasts for only 1--2 h in anesthetized animals ([@b53]; [@b41]; [@b34]). This constitutes the classic preconditioning or first window of myocardial protection. Of note, later experimental studies revealed that, while the provided protection is lost after this reperfusion interval and the heart remains unprotected for several hours, the protective effect re-appears after 24 hours and lasts up to 72 hours ([@b91]; [@b90]). This is the delayed phase of preconditioning or the second window of protection, which starts with no additional intervention, it is more prolonged although less robust.

The golden standard of the effectiveness of preconditioning is the reduction of the infarct size ([Figure 1](#fig1){ref-type="fig"}). However, there is a series of other benefits obtained from preconditioning and among these are the reduction of lethal arrhythmias and the better recovery of post-ischemic left ventricular function ([@b82]; [@b73]; [@b91]).

![The effect of ischemic preconditioning on infarct size after ischemia/reperfusion. Upper panel:infarct size expressed as percent of risk zone size in control and preconditioned (IPC) rabbit hearts (from [@b39]); lower panel: the absolute infarct volume plotted against absolute risk zone volume from control (closed symbols) and preconditioned (open symbols) hearts (from [@b38]).](vhrm0305-629-01){#fig1}

After the initial studies that elucidated the natural history of preconditioning in terms of the proper ischemic stimuli and time intervals, later experimental studies investigated the mechanisms that are involved in the protection mediated by preconditioning. The first breakthrough in this direction was the report by Downey and colleagues ([@b53]) that the adenosine A1 receptor acts to trigger ischemic preconditioning's protection in the rabbit heart, revealing that ischemic preconditioning is receptor mediated. It has now become established that the protection is receptor mediated, and a major objective in recent years has been the identification of the triggers, mediators and end effectors in the myocyte that are activated during ischemic preconditioning.

Activation of specific receptors on the cardiomyocyte cell membrane such as adenosine A1 and A3, bradykinin B2, α~1~-adrenergic, δ-opioid, and others, initiate a series of signal transduction cascades that carry the signal for protection and those presumably terminate on one or more end-effectors ([@b53]; [@b11]; [@b79]). In recent years, much research has focused on the key role of the mitochondrial K~ATP~ channel as both a trigger and distal effector in preconditioning with equivocal results ([@b68]; [@b20]; [@b76]; [@b37]; [@b65]). The signal transduction pathways downstream of the trigger are complex and a detailed description is beyond the scope of this review. However, it is clear that multiple protein kinases are involved, notably one or more isoforms of protein kinase C, at least two tyrosine kinases (eg, Src and PI3 kinase), as well as mitogen-activated protein kinases ([@b53]; [@b36]; [@b53]; [@b53]; [@b53]). Reperfusion injury salvage kinase (RISK) pathway has emerged as a concept and describes a group of survival protein kinases, which include Akt and Erk1/2 that confer powerful cardioprotection against lethal reperfusion injury when specifically activated at the time of reperfusion ([@b30]). The cardioprotective effect of ischemic preconditioning is completely aborted by inhibiting RISK pathway ([@b53]).

More recently another endogenous mechanism of protection, called postconditioning, was described. In brief, a series of very short-lived episodes of ischemia and reperfusion applied at the onset of reperfusion after an index ischemic event reduce the infarct size. Postconditioning is more easily applicable and does not require fore-knowledge of a potentially lethal ischemic event. RISK pathway is also involved in the cardioprotective mechanism of postconditioning and the inhibition of PI3 kinase abrogates protection conferred by postconditioning ([@b86]). It has been suggested that the RISK pathway "unites" both ischemic preconditioning and postconditioning at the time of reperfusion ([@b30]).

Preconditioning in humans
=========================

The acquired experience from the experimental studies was transferred to humans and the protective effect of preconditioning was examined using direct or indirect observations ([@b46], [@b47]; [@b1]; [@b48]; [@b44]). It is difficult to transfer the strict laboratory conditions regarding the number and the duration of episodes of ischemia and reperfusion, into the clinical reality, so much for practical reasons as well as for ethical reasons. Thus, the final end points for the assessment of protection in humans are more or less indirect. Furthermore, the precise estimation of the infarct size and the area at risk is not very easy to be determined in humans and therefore the beneficial effect of preconditioning is difficult to be assessed. However, as in the experimental models, other surrogate end-points are used for the expression of the salutary effect of preconditioning and among these are the reduction of the episodes of angina after an initial episode, the reduction of ST deviation on the electrocardiogram, the reduction of lethal arrhythmias, a smaller peri-operative infarction, a better survival of the patients with pre-infarction angina and others ([@b84], [@b85]; [@b40]; [@b21]).

The preconditioning studies can be divided into observational, provocative, and pharmacological. In the first category belong those studies where the patients describe alleviation of their symptoms or there is an objective method which can confirm the benefit of preconditioning. In fact, many patients report an episode of angina early in the morning, called walk-through or warm up angina and they remain free of symptoms later and for the rest of the day ([@b72]; [@b80]). There are a large number of clinical studies which have shown that pre-infarction angina acts as preconditioning stimulus and the patients develop smaller CK-determined myocardial infarction in comparison to the patients without pre-infarction angina. In the objective studies, it is feasible to describe the effect of an intervention that may act as a preconditioning analogue. In this regard, less ST segment shift, less extent of angina and less lactate production at the second balloon inflation compared to the first are some surrogate end-points attributed to an effect called coronary angioplasty-related preconditioning ([@b84], [@b85]). Furthermore, there is evidence that the second exercise treadmill test becomes better in comparison to the first and this may express an early or delayed preconditioning effect ([@b69]). Objective description of preconditioning has been also obtained from histological studies of tissue samples like atrial trabeculae or ventricular tissue taken at the time of operation or by the peripheral markers that have been used for the expression of preconditioning ([@b30]; [@b42]).

Another interesting issue is the pharmacological stimulation of preconditioning and the expectation that several agents involved in the mechanism of protection could become safe and easily applicable preconditioning mimetics. Adenosine, acadesine, ACE inhibitors which prevent bradykinin degradation, nicorandil, and others have been used in clinical studies. In the AMISTAD study, adenosine has been used in parallel with thrombolysis in patients with evolving myocardial infarction and resulted in reduction of the infarct size in anterior myocardial infarction despite the fact that it was administered after the onset of chest pain ([@b57]). In the AMISTAD II study, the adenosine was given in anterior myocardial infarctions only at two different doses and again it was shown that at a dose of 70 μg/kg min for 3 hours and in parallel with thrombolysis, it reduced the infarct size especially if the thrombolysis started within the first 3 hours ([@b74]). Acadesine, which is an agent that facilitates the effect of adenosine, was used in patients who underwent CABG. Patients treated with acadesine had fewer postoperative myocardial infarctions and better clinical outcome ([@b59]). Nicorandil, which opens the mitochondrial K~ATP~ channels, has been used in two multicenter clinical trials, CEASAR-2 and IONA, with very promising results ([@b70]; [@b50]). These clinical results suggest that the cardioprotective effects of preconditioning, well described in animal studies, do appear to translate to clinical setting. However, direct translation of experimental observations to therapeutic intervention is hampered by factors encountered in clinical practice such as the necessity of proper time of intervention, the proper duration of the treatment and of course the appropriate dosage of drugs.

Apoptosis in the heart
======================

While ischemic injury has long been considered to result in necrotic tissue damage, studies over the past 15 years have focused attention on apoptosis as a significant component of cell loss during reperfusion injury following myocardial infarction ([@b23]; [@b19]; [@b23]; [@b16]). Myocardial apoptosis has also been documented in response to a variety of other cardiac stresses including pressure or volume overload, heart failure, diabetic cardiomyopathy, atherosclerosis and anti-cancer agents ([@b29]; [@b18]; [@b87]; [@b83]).

Cardiomyocytes undergoing necrosis and apoptosis show characteristic but morphologically and biologically distinct features. Necrosis, also called oncosis in the setting of ischemia/reperfusion, is an uncontrolled, irreversible process characterized by severe cell swelling, ATP depletion, denaturation and coagulation of cytoplasmic proteins, breakdown of cell organelles and disruption of cell membrane ([@b81]; [@b58]). It is a destructive process as release of cellular content into the surrounding environment provokes inflammation and can cause further damage or death to neighboring cells. In contrast, apoptosis is a genetically controlled, highly regulated process whereby the cell commits suicide without inducing inflammatory response. Apoptosis usually requires energy and it is characterized by cell shrinkage, chromatin condensation, DNA fragmentation, membrane blebbing and formation of apoptotic bodies ([@b58]; [@b75]; [@b8]). The hallmark of apoptosis in intact cells is endonucleolytic digestion of nuclear DNA into oligonucleosome-sized fragments (200 bp), in contrast to nonspecific degradation of DNA into pieces of random size after loss of membrane integrity.

The regulated disassembling of cellular contents, which is a feature of apoptosis, is largely conducted by a family of cysteine dependent aspartate-directed proteases, the caspases ([@b89]). Fourteen members of this family have been identified in mammals. Caspases-2, -9, -8, and -10 are considered apoptosis initiators, and serve to cleave and activate apoptosis effectors (caspases-3, -6, and -7). All caspases are synthesized as zymogens that contain a prodomain, a large subunit and a small subunit, and activation of these enzymes is by proteolytic cleavage. Once activated, initiator caspases cleave and activate effector caspases and a proteolytic cascade is initiated.

There are two principal pathways that lead to caspase activation: the extrinsic and intrinsic cell death pathways ([@b13]). The extrinsic pathway requires the activation of cell surface death receptors (DRs) by specific ligands, and allows the cell to respond directly to the immediate environment ([Figure 2](#fig2){ref-type="fig"}). The vast majority of death receptors belong to the tumor necrosis factor receptor (TNFR) superfamily, which includes Fas, TNFR1, and DR3--DR6. The binding of death ligands, such as Fas ligand or TNF-α, to their cognate receptors at the plasma membrane causes homotrimerization of the receptor and recruitment of specific adaptor proteins, such as Fas-associated death domain and procaspase-8, into a death-inducing signaling complex (DISC). This, in turn, leads to activation of initiator caspase-8, which subsequently activates effector caspases 3, 6, and 7 ([@b33]; [@b13]). In contrast, in the intrinsic pathway ([Figure 3](#fig3){ref-type="fig"}), the mitochondria detect and respond to unfavorable changes in the internal environment and play a central role in the integration and execution of a wide variety of apoptotic signals. The mitochondria provide the energy required for execution of the apoptotic program and release of pro-apoptotic proteins such as cytochrome c, endonuclease G, and apoptosis-inducing factor. Release of these substances occurs during opening of the mitochondrial permeability transition (MPT) pore, a large non-selective ion channel in the outer mitochondrial membrane. Gating of the MPT pore is controlled by a combination of calcium, redox potential, pH and transmembrane voltage; when the MPT is opened, the normally impervious mitochondrial membrane undergoes a reversible transition to permeability ([@b95]; [@b9]). Either brief or sustained MPT opening can lead to apoptosis ([@b23]). On release from mitochondria, cytochrome c forms a complex with procaspase-9 and a cytosolic cofactor, Apaf-1 ([@b52]; [@b96]). In the presence of sufficient ATP, caspase-9 undergoes autocatalytic cleavage to create an active 'apoptosome' that cleaves caspase-3 and initiates the apoptotic program. Thus, the extrinsic and intrinsic pathways have different initiator caspases but converge at the level of the effector caspases.

![Schematic representation of the death receptor (extrinsic) pathway of caspase activation to provoke the mechanism of apoptosis.](vhrm0305-629-02){#fig2}

![Schematic representation of the mitochondrial death (intrinsic) pathway leading to the formation of apoptosome, activation of caspases and apoptosis.](vhrm0305-629-03){#fig3}

The intrinsic pathway of apoptosis is regulated by members of the Bcl-2 family. This family is composed of anti-apoptotic eg, Bcl~2~, Bcl-xL, Bcl-w, A1, and Mcl-1 and pro-apoptotic proteins eg, Bax, Bad, Bak, Bid, Bim, Bnip3, Bnip3L (Nix), and Bik. All of these proteins possess up to four conserved regions known as Bcl-homology (BH) domains ([@b12]). The principal site of action of the Bcl-2 family proteins is at the mitochondria, where they regulate cytochrome c release and caspase activation. The exact mechanisms by which Bcl-2 proteins modulate apoptosis are still subject to much debate and controversy. One hypothesis is that both pro-apoptotic and anti-apoptotic Bcl-2 proteins bind directly to components of the mitochondrial pore, leading to either its opening or closure, respectively ([@b26]; [@b60]). A second hypothesis is that upon activation, pro-apoptotic members such as Bax and Bak are inserted into the outer mitochondrial membrane where they oligomerize to form a protein-permeant pore of their own ([@b60]).

The most clinical relevant stimulants, which initiate the process of apoptosis apart from ischemia/reperfusion, include pressure or volume overload, cellular calcium overload, oxygen derived free radicals, increased levels of catecholamines and angiotensin II, Fas ligand, TNF-α, as well as decreased coronary flow reserve ([@b45]; [@b77]). It is obvious that there is a complex interrelation between all the above factors. Decreased coronary flow reserve, for example, results in periods of ischemia and reperfusion and in generation of oxygen-derived free radicals. Angiotensin II may cause pressure overload and heart failure results in increased circulating catecholamine levels. All the above mentioned conditions may lead to contractile dysfunction of the heart, to dysrhythmias and to cell death because of apoptosis or necrosis. The rationale of current therapy is mainly to modify myocyte dysfunction and to minimize the intensity of the lethal injury acting on the heart. Well documented clinical interventions such as restoration of ischemia by pharmacological or interventional means, valve replacement or surgical correction of any anatomic abnormalities which may be considered responsible for pressure or volume overload, use of beta blockers, ACE inhibitors or angiotensin II receptor antagonists may prevent, suppress or restore cardiac dysfunction. However, preservation of cells subjected to lethal injury remains an attractive goal and inhibition of cardiac myocyte apoptosis may represent a novel approach for treatment of cardiac disease. For this reason, a better understanding of the pathways of apoptosis and their regulation is required. Therapeutic approaches such as the use of inhibitors of TNF-α, caspases and sodium-hydrogen exchanger, upregulation of insulin like growth factor-1, antioxidants, ischemic preconditioning, which will be discussed in the next section, and others are currently under investigation ([@b22]; [@b45]).

Preconditioning and apoptosis
=============================

Accumulating evidence from in vivo and in vitro studies suggests that ischemic preconditioning significantly reduces DNA fragmentation ([Figure 4](#fig4){ref-type="fig"}) and apoptotic myocyte death that is associated with ischemia/reperfusion in isolated rabbit and rat heart ([@b24]; [@b61]; [@b64]; [@b94]; [@b39]). In addition, activation of receptors that are involved in the initiation of the mechanism of preconditioning, such as δ-opioid and bradykinin, also results in reduced apoptosis after ischemia/reperfusion (Okubo et al 2004; [@b17]). It is clear from these studies that attenuation of apoptosis by ischemic preconditioning is associated with a reduction in infarct size analysed early at reperfusion. It is not known, however, whether a reduction in infarct size measured days after reperfusion is achieved by inhibiting apoptosis since apoptosis progresses after reperfusion over a number of days. The potential mechanisms underlying preconditioning attenuated myocardial apoptosis have not been fully clarified and they are under intense investigation. However, a number of mediators have been implicated.

![Effect of ischemic preconditioning on DNA fragmentation in rabbit hearts subjected to ischemia/reperfusion Lane 1 represents control non-ischemic tissue; lane 2 represents ischemic tissue after ischemia without reperfusion; lanes 3 and 4 represent ischemic tissue after ischemia/reperfusion in nonpreconditioned and preconditioned hearts, respectively. M, marker lane (from [@b39]).](vhrm0305-629-04){#fig4}

Several studies have shown that preconditioning inhibits apoptosis by reducing the burst of reactive oxygen species generated from inflammatory cells (ie, PMNs and macrophages) and noninflammatory cell types (ie, endothelial cells and myocytes). In this regard, antioxidants and free radical scavengers have been reported to inhibit the appearance of apoptosis ([@b43]; [@b94]). Other studies have implicated that preconditioning reduces myocardial apoptosis through altering the balance between anti-apoptotic and pro-apoptotic proteins, the release of cytochrome c from mitochondria, caspase activation, and activation of protein kinase C isozymes. Preconditioning causes a decrease in pro-apoptotic Bax and increase in the anti-apoptotic Bcl-2 proteins resulting in an altered Bcl-2/Bax ratio and attenuation of cytochrome c release from mitochondria ([@b61], [@b62]; [@b64]). Inhibition of caspase activity, a key event in the development of apoptosis, has also been demonstrated in preconditioning ([@b71]). A reduction in ceramide production during sustained ischemia has been suggested to reduce apoptosis in rabbit hearts ([@b3]). However, an interrelationship between changes in the expression of Bcl-2 family proteins, mitochondrial activity and reduction of apoptosis after ischemia/reperfusion by ischemic preconditioning needs to be further investigated in *in vivo* models.

As discussed above, PKC has a central role in ischemic preconditioning. In particular, activation of PKCε is important in the preservation of cell viability. Although the effect of ischemic preconditioning on necrosis through activation of PKC isoforms has been intensively investigated ([@b91]), only a few studies have shown that preconditioning reduces apoptosis by a PKC-dependent pathway. [@b66] showed that blockade of PKC may interrupt the protective effect of preconditioning and simultaneously it may promote the mechanism of apoptosis. Furthermore, PKCε but not PKCδ is involved in the inhibition of apoptosis by preconditioning after simulated ischemia and reoxygenation ([@b54]).

The mitochondrial K~ATP~ channels significantly contribute to the mechanism of protection in ischemic preconditioning by the generation of the oxygen-derived free radicals. Opening of these channels by pharmacological means like nicorandil or diazoxide, trigger the mechanism of protection while the addition of 5HD blunts this effect ([@b68]; [@b76]; [@b53]; [@b65]). It is of interest that diazoxide is also capable in preventing apoptosis and again the simultaneous use of 5HD abolishes this benefit ([@b2]). In addition to direct effects on mitochondrial function, opening of mitochondrial K~ATP~ channels may have secondary effects on cell signaling such as activation of PKCε ([@b55]).

As mentioned above, activation of kinases of the RISC pathway has been implicated in mediating the cardioprotection associated with ischemic preconditioning ([@b32]; [@b30]). Recent studies have shown that pharmacological activation of these kinases is associated with recruitment of anti-apoptotic signaling components such as the phosphorylation and inhibition of the proapoptotic proteins Bax and Bad, the inhibition of caspase 3 activation, the phosphorylation and activation of p70S6K (which acts to inhibit Bad) and the phosphorylation and activation of the antiapoptotic protein Bcl-2 ([@b27]; [@b30]). In addition, the inhibition of the mitochondrial permeability transition pore (MTP), a mitochondrial channel which mediates cell death at the time of myocardial reperfusion by uncoupling oxidative phosphorylation and inducing mitochondrial swelling ([@b30]), has been identified as a downstream target of the RISK pathway ([@b14]; [@b7]). Although it has been shown that ischemic preconditioning prevents the increased permeability of the transition pore by the activation of kinases, Akt, PI3 kinase, and ERK1/2, the mechanism through which the RISK pathway inhibits the opening of the MTP is unclear.

In conclusion, ischemic preconditioning is a protective mechanism in limiting the infarct size and there is a great body of evidence that it reduces both necrosis and apoptosis. We expect that in the future the acquired experience and the increased knowledge of the underlying mechanisms in preconditioning and apoptosis would allow a more appropriate use of the proper pharmacological agents that would mimic preconditioning and that confer reduction of both necrosis and apoptosis. However, the translation of the laboratory findings in the clinical practice should be performed very cautiously and with prudence.
